Emcure Pharmaceuticals saw an 8.2% rise in net profit for Q1FY25, reaching Rs 153 crore due to strong sales in India and abroad. Revenue from operations increased by 16.6% to Rs 1,815 crore. The company reported growth across Europe and Canada, emphasizing its successful integration of Sanofi’s cardiovascular brands.
| Subscribe To Our Free Newsletter |
